H.C. Wainwright raised the firm’s price target on Belite Bio (BLTE) to $100 from $60 and keeps a Buy rating on the shares following the Q3 report. Considering the annual price range of Syfovre and Izerway between $13,000 and $26,000, the firm updated its projected price for tinlarebant from $6,000 to $9,500 in the model.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BLTE:
- Belite Bio Advances in Retinal Disease Trials
- Belite Bio Advances in Tinlarebant Trials, Appoints New CMO
- Belite Bio reports Q3 EPS (28c), consensus (29c)
- Is BLTE a Buy, Before Earnings?
- Belite Bio Offers New Warrant Opportunities to Investors
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
